Generic Otiprio Availability

Last updated on Jun 11, 2025.

Otiprio is a brand name of ciprofloxacin otic, approved by the FDA in the following formulation(s):

OTIPRIO (ciprofloxacin - injectable, suspension;otic)

• Manufacturer: ALK ABELLO
  Approval date: December 10, 2015
  Strength(s): 6% (60MG/ML) (discontinued) ^[RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Otiprio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Otic gel formulations for treating otitis externa
  Patent 11,040,004
  Issued: June 22, 2021
  Inventor(s): Lebel Carl
  Assignee(s): OTONOMY, INC.
  

  Disclosed herein are methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

  Patent expiration dates:

  • November 12, 2037
    
    ✓ 
    Patent use: THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
• Ciprofloxacin otic composition and kits and method for using same
  Patent 11,246,863
  Issued: February 15, 2022
  Inventor(s): Coleman; Scott H. et al.
  Assignee(s): ALK-ABELLÓ, INC. (Bedminster, NJ)
  

  Disclosed herein are otic product kits for administration of a sterilized formulation. In some embodiments, the otic product kit comprises: an aseptic container containing the sterilized formulation; a syringe; and an administration needle connectable to the syringe, wherein the sterilized formulation comprising: from about 5.5 wt % to about 6.5 wt % multiparticulate ciprofloxacin; from about 15 wt % to about 17 wt % poloxamer 407; and water. Also disclosed herein are methods of preparing and administrating the sterilized formulation. In some embodiments, the method comprising (1) transferring the sterilized otic formulation from an aseptic container to a syringe through a preparation needle; (2) replacing the preparation needle with an administration needle; and (3) injecting the sterilized otic formulation from the syringe through the administration needle into the ear of a patient.

  Patent expiration dates:

  • November 27, 2038
    
    ✓ 
    Drug product
• Controlled release antimicrobial compositions and methods for the treatment of otic disorders
  Patent 11,369,566
  Issued: June 28, 2022
  Inventor(s): Lichter; Jay et al.
  Assignee(s): ALK-ABELLÓ, INC. (Bedminster, NJ); THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
  

  Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

  Patent expiration dates:

  • April 21, 2029
    
    ✓ 
    Drug product
• Controlled release antimicrobial compositions and methods for the treatment of otic disorders
  Patent 8,318,817
  Issued: November 27, 2012
  Inventor(s): Lichter; Jay et al.
  Assignee(s): Otonomy, Inc. (San Diego, CA); The Regents of the University of California (Oakland, CA)
  

  Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

  Patent expiration dates:

  • April 27, 2030
    
    ✓ 
    Patent use: TREATMENT OF OTIC INFECTION OR INFLAMMATION
• Controlled release antimicrobial compositions and methods for the treatment of otic disorders
  Patent 9,205,048
  Issued: December 8, 2015
  Inventor(s): Lichter; Jay et al.
  Assignee(s): OTONOMY, INC. (San Diego, CA); THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
  

  Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

  Patent expiration dates:

  • April 21, 2029
    
    ✓ 
    Patent use: TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
• Sterilization of ciprofloxacin composition
  Patent 9,220,796
  Issued: December 29, 2015
  Inventor(s): Coleman Scott H. & Liaw Wei-Cheng & Wroblewski Jerry & Savel Robert
  Assignee(s): OTONOMY, INC.
  

  Disclosed herein are methods of making sterilized ciprofloxacin compositions. In some embodiments, the method includes the steps of: (a) forming an aqueous suspension comprising ciprofloxacin particles; (b) heating the aqueous suspension comprising ciprofloxacin particles at a temperature range of from about 100° C. to about 120° C.; and (c) allowing the aqueous suspension comprising ciprofloxacin particles to cool down. Also described herein are otic formulations containing ciprofloxacin formed by the disclosed methods, and therapeutic use of such otic formulation for providing sustained release of ciprofloxacin into the ear for treating various otic disorders and conditions.

  Patent expiration dates:

  • July 1, 2035
    
    ✓ 
    Drug product
• Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders
  Patent 9,233,068
  Issued: January 12, 2016
  Inventor(s): Lichter; Jay et al.
  Assignee(s): OTONOMY, INC. (San Diego, CA); THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
  

  Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

  Patent expiration dates:

  • December 11, 2029
    
    ✓ 
    Drug product
• Controlled release antimicrobial compositions and methods for the treatment of otic disorders
  Patent 9,603,796
  Issued: March 28, 2017
  Inventor(s): Lichter; Jay et al.
  Assignee(s): OTONOMY, INC. (San Diego, CA); THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
  

  Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

  Patent expiration dates:

  • April 21, 2029
    
    ✓ 
    Patent use: THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
    ✓ 
    Drug substance
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer